Harmony Biosciences Holdings (HRMY) Cash & Equivalents (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Cash & Equivalents data on file, last reported at $472.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 3.4% year-over-year to $472.4 million; the trailing twelve-month figure through Mar 2026 stood at $472.4 million (down 3.4% YoY), and the FY2025 full-year result was $355.6 million, down 16.65% from the prior year.
• Cash & Equivalents grew to $472.4 million in Q1 2026, from $355.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $647.0 million in Q3 2025 to a low of $194.6 million in Q2 2022.
• A 5-year average of $370.9 million and a median of $355.6 million in 2025 frame the typical range for Cash & Equivalents.
• Peak annual rise in Cash & Equivalents reached 67.02% in 2025, while the deepest fall reached 16.65% in 2025.
• Tracing HRMY's Cash & Equivalents over 5 years: stood at $286.9 million in 2022, then climbed by 8.64% to $311.7 million in 2023, then soared by 36.88% to $426.6 million in 2024, then slipped by 16.65% to $355.6 million in 2025, then soared by 32.85% to $472.4 million in 2026.
• Business Quant data shows HRMY's Cash & Equivalents at $472.4 million in Q1 2026, $355.6 million in Q4 2025, and $647.0 million in Q3 2025.